Therapeutic efficacy of rolipram delivered by PgP nanocarrier on secondary injury and motor function in a rat TBI model

Nanomedicine (Lond). 2022 Mar;17(7):431-445. doi: 10.2217/nnm-2021-0271. Epub 2022 Feb 21.

Abstract

Aim: To develop poly(lactide-co-glycolide)-graft-polyethylenimine (PgP) as a nanocarrier for the delivery of rolipram (Rm) and evaluate the therapeutic efficacy of Rm-loaded PgP (Rm-PgP) on secondary injury and motor function in a rat traumatic brain injury (TBI) model. Materials & methods: Rm-PgP was injected in the injured brain lesion immediately after TBI using a microinjection pump. Secondary injury pathologies such as inflammatory response, apoptosis and astrogliosis were assessed by histological analysis and functional recovery was assessed by assorted motor function tests. Results: Rm-PgP restored cyclic adenosine monophosphate level in the injured brain close to the sham level and Rm-PgP treatment reduced lesion volume, neuroinflammation and apoptosis and improved motor function at 7 days post-TBI. Conclusion: One single injection of Rm-PgP can be effective for acute mild TBI treatment.

Keywords: PgP nanoparticle; apoptosis; controlled cortical impact; functional recovery; neuroinflammation; rolipram; traumatic brain injury.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Apoptosis
  • Brain Injuries, Traumatic* / complications
  • Brain Injuries, Traumatic* / drug therapy
  • Brain Injuries, Traumatic* / pathology
  • Disease Models, Animal
  • Polyethyleneimine / pharmacology
  • Rats
  • Recovery of Function
  • Rolipram / pharmacology

Substances

  • Polyethyleneimine
  • Rolipram